Preclinical research to focus on developing therapies based on MaxCyte’s proprietary CARMA platform – CARMA has potential for broad applicability against solid or liquid tumor indications Gaithersburg, MD, December 21, 2016 – MaxCyte®, Inc. today announces a strategic collaboration with
Biotech industry veteran to lead alliance-building efforts for MaxCyte’s proprietary CARMA platform Gaithersburg, Maryland – November 2, 2016 – MaxCyte, Inc., a developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and
Gaithersburg, MD, 29 September 2016 – MaxCyte®, Inc., an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and
Released : September 06, 2016 07:00 RNS Number : 0072J MaxCyte, Inc. 06 September 2016 MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems Gaithersburg, MD , 6 September 2016 - MaxCyte®, Inc., the
